TY - JOUR
T1 - High frequency of neutralizing antibodies to type I Interferon in HIV-1 patients hospitalized for COVID-19
AU - Scordio, Mirko
AU - Frasca, Federica
AU - Santinelli, Letizia
AU - Sorrentino, Leonardo
AU - Pierangeli, Alessandra
AU - Turriziani, Ombretta
AU - Mastroianni, Claudio M.
AU - Antonelli, Guido
AU - Viscidi, Raphael P.
AU - d'Ettorre, Gabriella
AU - Scagnolari, Carolina
N1 - Funding Information:
This work was supported by a grant to S.C. (Scagnolari Carolina, Gilead Sciences, Fellowship Program 2021, Title of the project: Development of a new integrative approach for monitoring SARS-CoV-2 infection-induced versus vaccine-acquired innate and T cell immunity in HIV-1 infected patients).
Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022/8
Y1 - 2022/8
N2 - The presence of anti-IFN neutralizing antibodies (NAB) has been reported in critically ill COVID-19 patients. We found that 87.5% (7/8) of HIV-1 patients co-infected with SARS-CoV-2 had serum anti-IFN-I NAB against IFN-α subtypes, IFN-β and/or IFN-ω. Anti-IFN-I NAB were also detected in oropharyngeal samples. Patients with NAB were males, and those with high serum anti-IFN-α/ω NAB titer had severe illness and exhibited reduction in the expression of IFN-stimulated genes. Thus, high titer of anti-IFN-α/ω NAB may contribute to the greater severity of COVID-19 in HIV-1 infected patients.
AB - The presence of anti-IFN neutralizing antibodies (NAB) has been reported in critically ill COVID-19 patients. We found that 87.5% (7/8) of HIV-1 patients co-infected with SARS-CoV-2 had serum anti-IFN-I NAB against IFN-α subtypes, IFN-β and/or IFN-ω. Anti-IFN-I NAB were also detected in oropharyngeal samples. Patients with NAB were males, and those with high serum anti-IFN-α/ω NAB titer had severe illness and exhibited reduction in the expression of IFN-stimulated genes. Thus, high titer of anti-IFN-α/ω NAB may contribute to the greater severity of COVID-19 in HIV-1 infected patients.
KW - HIV-1
KW - HIV-1 and SARS-CoV-2 co-infection
KW - ISGs
KW - Interferon
KW - Neutralizing antibodies
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85134721868&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134721868&partnerID=8YFLogxK
U2 - 10.1016/j.clim.2022.109068
DO - 10.1016/j.clim.2022.109068
M3 - Letter
C2 - 35764258
AN - SCOPUS:85134721868
SN - 1521-6616
VL - 241
JO - Clinical Immunology
JF - Clinical Immunology
M1 - 109068
ER -